ARPA‑H awarded BioCurie up to $9.3 million to develop an AI‑driven, data‑centric platform aimed at accelerating and de‑risking gene‑therapy manufacturing. BioCurie will partner with academic and industry specialists—including Caring Cross, St. Jude Children’s Research Hospital and the Center for Breakthrough Medicines—to model, simulate and optimize viral and non‑viral process development. BioCurie says the platform will reduce trial‑and‑error process cycles, improve robustness across modalities and shorten timelines to clinical supply. Irene Rombel, BioCurie CEO and ARPA‑H principal investigator, framed the project as a step toward digital‑first manufacturing that can widen patient access by lowering costs and enabling more predictable scale‑up.